novarti report strong set result group sale grew ahead
consensu opinc grew ep grew yoy ahead consensu
tp increas
manag confid growth novarti rais guidanc fy mid
high teen growth oper incom level cse
comment expect movement higher end guidanc rang longer take
afinitor exjad gener meaning enter market
modest caution headwind includ flat qoq zolgensma growth cite
call due higher-than-expect attribut previou pent-up demand potenti
gener eros increas invest launch name beovu mayzent
fevipipr fail mild/moder asthma manag confid sever zeal
studi fail manag confid eosinophil sever luster studi due
note result alreadi in-hous compani recent
initi nasal polyp paediatr studi cs forecast po peak npv
rais core ep number averag reflect
growth driver out-performance continu mid-term
rais tp sfr reflect earn neutral rate reflect valuat
well execut risk new launch
catalyst risk look decemb day shed light
next wave late asset emerg pipelin fevipipr asthma luster
valuat novarti trade pe premium eu peer
novarti trade ev/npv vs eu peer
valuat metric
price-to-earnings rel local market
number share
price rel chart measur perform
swiss market ind close
spot exchang rate
legal entiti disclosur statu non-u analyst us disclosur credit suiss seek busi
compani cover research report result investor awar firm may conflict interest could
affect object report investor consid report singl factor make invest decis
profit tax
associ
chang work capit
cash non-cash item
flow oper
free cash-flow firm
flow invest
issuanc retir debt
cash-flow financ
chang net cash/debt
net debt start
chang net debt
net debt end
total equiti liabil
share wtd average mn
ratio valuat
net debt ebitda
novarti provid healthcar solut compani multi-national
group compani special research develop
manufactur market rang healthcar product led
scenario base pipelin success higher
peak sale cosentyx stronger sandoz biopharma
revenu gilenya patent life extens
grey scenario base pipelin success lower
peak sale entresto lower cosentyx peak sale
lower sandoz growth
price rel chart measur perform swiss market ind close
spot exchang rate
price
rais pharma product sale averag reflect key growth driver
out-performance continu mid-term
zolgensma reflect manag commentari broadli flat versu
also revisit revenu recognit assumpt ex-u zolgensma sale
previous assum revenu would spread across year per patient
still believ pay-for-perform model common europ note novarti
revenu recognit polici mean sale book front
margin assumpt continu assum increas invest grow gener
pressur
gilenya continu assum us revenu retain full durat
assum probabl preserv us sale driven patent
settlement court rule favour novarti
dilut share credit suiss post product credit suiss post product charl martineau univers toronto octob
sale singl digit cermid high singl digit cerhigh singl digit impact singl digitmid high singl digithigh singl low doubl line last yearin line low singl digitlow singl oper singl digit cerlow doubl digit- mid teen cermid-to-high teen growth impact op op op op financ adj tax mix share end use base ex alcon /aurobindo cs guidanc ex cs inc mth majorspricetarget sale growthl ep growthdiv yield sharenpv/ shareabbvi consensu consensu consensu consensu consensu consensu major nordisk major averag ex premium/ discount major averag premium/ discount charl martineau univers toronto octob
sensitivitylowzolgensma sma type approvalzolgensma sma type eu full data fevipipr asthma data-z failedzolgensma sma type strong file updateentresto failedparagon hf pef datacosentyx non-radiograph axial data nsclc data filingofatumumab relaps ms data -asclepio abstract bt -palladium jakavi sr agvhd novarti wet fda interim anl -combi-ifevipipr data-lust presbyopia data ascr datavis acut mi paradise-mi potenti yr endjakavi sr cgvhd datar daylondon charl martineau univers toronto octob
novarti result inc consc prob prob prob drug ex-diovan pharma ebit ebit margin sandoz ebit ebit margin expens lgroup product profit profit margin financi incom incom share credit suiss ps sfr charl martineau univers toronto octob
prob prob prob prob oper profit op oper margin oper profit incom roch pre incom gsk consum pre financi profit rate incom cs incom incom share data number share dilut number share chang credit suiss per share cs ep stand alon ex charl martineau univers toronto
strong double-digit top bottom line growth margin expans major
ofatumumab good efficaci rm
cosentyx met primari endpoint nr-axspa
repres innov medicin sale
growth driver contribut sale growth gx eros
sale growth strong us ex-u
strong momentum grow us dermatolog market yoy grow ahead
market
lead posit grow us spa market yoy grow ahead
prevent met primari endpoint week could add nr-axspa label
signific potenti growth across popul biolog penetr
nr-axspa opportun expans
info addit indic next day
solidifi posit soc hfref sale ytd
ytd
paediatr indic approv
paragon-hf largest hfpef outcom trial back approv hfref indic pre-
defin secondari endpoint subgroup analys support benefit regulatori
payer discuss on-going us submiss inclus data label on-going
discuss eu regul
broad access commerci patient medicaid patient cover
final approv rate label patient appropri appeal process
solid demand major lead academ center excel prescrib sinc
broad patient profil across age sma type incid preval popul
switch spinraza
work pent demand zolgensma expect similar
newborn screen newborn screen us expect reach
end
medicaid polici come place rapidli
interim strong data reinforc efficaci sma type
regulatori us await fda feedback intrathec file approach eu chmp
opinion expect extens set question regard manufactur japan
strong start us launch
highli competit label similar efficaci fewer inject without compromis
efficaci flexibl
reduct central retin subfield thick across treatment arm
comprehens trial program hold potenti new indic better profil
beovu core indic talon head-to-head superior vs eylea
merlin studi cover patient pop requir
conveni sc option need infus center
want shift focu relaps progress
acceler diagnosi onboard need sale ramp-up
live prefer unrestrict access
day lag patient interest get patient board pay rx want
shorten lag
expect chmp opinion late
zeal failur lung function confirm clean safeti profil didnt stratifi
eosinophil use dose
luster determin exacerb benefit moderate-to-sever asthma result
launch go well
first therapi abc patient mutat
approxim abc popul mutat
potenti expand beyond abc program start tnbc ovarian
believ medicin blockbust
inhibitor consist superior os two trial
believ uniqu profil mechanist differenti pathway
postmenopaus pt pre- peri-menopaus
os data readout
financi
cc opinc driven sale product program impact
strong cash flow
mainli driven biopharm continu oper pt cc
favour medicaid one-tim adjust
sale revis upward expect grow high singl digit
oper incom revis upward expect grow mid high teen
innov medicin revis upward grow high singl digit low doubl digit
sandoz revis upward grow low singl digit
driver headwind
driver innov medicin growth launch uptak product program benefit
drag potenti gener eros mainli afinitor exjad matur ophtha brand
potenti resolut valsartan competitor suppli shortag increas invest pre-
launch launch beovu mayzent piqray ofatumumab
currenc impact net sale
effect strengthen usd diminish time
expect
expect
expect
currenc impact core opinc
expect
expect
expect
 level comfort consensu number zolgensma enough preval
driver penetr incid popul goal high coverag us screen
continu drive switch reach highest level coverag continu
opportun switch global launch market entri substanti sale
opportun outsid us abil launch europ middl east latam asia
zolgensma iv lot catalyst come
 gilenya settlement time-frame would come market time
settlement
recent court injunct cover gener manufactur disclos settlement detail
would expect point next year rule district court import rule
appeal confid given languag initi rule restrain order put place feel
good posit
 moment get patient drug zolgensma access
improv
preval popul continu avail still climb incid captur
becom preval patient avail us term dynam preval pt continu work
access environ medicaid current goal increas cours next year
continu journey educ long-term data reluct switch insur
cover medicin key dynamics/focu access continu educ
 piqray test rate seen moment coverag type patient
late line earlier driven companion diagnost
patient mutat usual poor prognosi receiv
therapi broad coverag treatment test cover nccn guidelin pleas
uptak test might patient later line expect major come
treatment expect continu demand pleas perform
 see momentum busi develop
similar set factor impact launch continu drive growth driver
goal save oncolog set gener horizon launch set well
strong
 sens much zolgensma us vs exu speed reimburs speed
exu next year
vast major sale come us paid patient europ franc atu
countri portug germani broad reimburs nusinersen think
strong advocaci use zolgensma think strong cost effect analysi
 data file base fail trail entresto aducumumab new realm fda
look entresto result discuss fda express interest see
result submit end year approv medicin reduc eject
sizeabl safeti data base adjac popul unclear boundari popul
reduc preserv grey zone believ regul
encourag file data
 cosentyx trx nbrx stall sinc launch skyrizi
delight perform go strongli faster market normal see fluctuat
nbrx solid across year skyrizi expand market take share older agent
name tnf two-third patient manifest beyond skin look
care dynam nbrx feel good trend
 amort intang pharma significantli expect go
forward per persist
see acquir medicin increas amort accord expect
patent life avexi xiidra roughli level would expect go forward
pend
 us suffer neg inventori movement entresto quantifi
respons rebat discount price increas
line previou year seen revenu reduct true up yoy
expect realli strong comfort full-year consensu inventori one
two day hardli fluctuat compani key brand ensur overal see sale line
demand noth concern strong underli demand
 zolgensma strong discuss second dose fda wait highest dose data
convers fda
submit two dose fda convers yet fda make
progress high dose fact need posit data need
 feel addit share buyback
free cash flow go well continu see share buy back capit alloc prioriti
complet look capit overal first prioriti organ invest second
dividend extern growth share buy back come fourth would make announc
publicli go see on-going share buyback
 write back inventori impact margin see similar beovu
launch provis prior approv write launch inventori accord ifr
impact seen thrill feedback
top retina specialist us physician realli make decis base dri abil medicin
dose interv safeti cost believ product deliv four physician
impress price excit use treat patient quickli describ
 zolgensma launch paid perform proport dose achiev
pay perform program
featur mani contract privat insur met
mileston contract present five-year data continu see deterior
five year small portion patient ensur appropri revenu deduct
updat everi quarter base data
 fevipipr say perform zeal
inconsist complet miss
surpris result conduct moder popul broad unselect
popul origin intent alway sever popul elev eosinophil count
 respiratori view franchis strategi go given fevipipr result
posit result tripl asthma qmf built top copd drug
look optim way launch entir portfolio final result fevi shape pictur ideal
posit xolair fevi qvm move onto advanc therapi portfolio look
indic better view longer term outlook
 sandoz margin sustain margin underli growth op profit
improv quarter
op except strong impact one-tim growth margin driven
biolog grow geograph mix partli off-set price eros us goal
improv transform sandoz track
 fevipipr say po hit result luster high
would know result zeal
go back studi class well studi studi see
benefit studi high eosinophil patient saw benefit
zeal luster differ effort luster sever primarili high eosinophil
zeal result larg line request us look cant say read
 number patient treatment zolgensma
divid total sale net rang patient treat also mani patient
earli access trial
 mayzent board issu would differ ms therapi logist vs
nbrx see show physician see valu lag due baselin test free drug
market coupl month see opportun acceler alway said first
would educ challeng diagnos spm need continu work
educ need certain genet test one compon logist challeng
 cosentyx nraxspa penetr rate low due lack therapi discuss
experi europ tell us barrier uptak improv
tnf approv past indic europ thing make strong
access argument us europ improv diagnost rate includ mri
 give us contribut oral solid sandoz lack depreci
biolog roughli sandoz growth flattish oral solid
 think dispos aurobindo occur
work close hope approv author next month
 sandostatin lar impact seen europ proport row europ
sandostatin sale broadli line last year still growth us europ see first
eros gener one gener compani market authoris uk spain franc
switzerland germani approv see first eros germani expect may
focus eros market us news limit gener
entri one compani slow eros product easi suppli larg volum hard
manufactur
 aimovig slower start europ perspect market trajectori updat litig
reimburs strong uptak extrem well germani
difficult get reimburs europ given compar product us remain well
differenti year data access first market familiar expect continu
perform updat litig
 updat pegfilgrastim biosimilar file us
confid qualiti dossier expect review complet soon
 sens level zolgensma
newborn screen place see awar gene therapi newborn
screen high correl awar patient diagnos later specialist
centr hard get switch aspir coverag
 fevi comment plan file slide appendix say luster
complet data hand
order file need studi pool analysi across program initi readout
luster studi await luster data spirit studi safeti well
 ramp beovu launch trajectori expect vs eylea launch
reiter physician excit use fluid factor treatment
switch decis believ beovu major player world-class team place us
launch
 colour phrase even distribut type age zolgensma
provid granular seen uptak patient
seen even distribut type
 fevi thought mechanist reason zeal result
select agent classic bronco dilat diseas would
respons agent biolog moder popul signific improv
expect see better result patient high eosinophil
 outlook china entresto cosentyx threat
see import opportun overal want doubl five year
driven new launch last two year nda expect
nda submiss sit overal believ want well posit portfolio
avail china china growth high innov portfolio drive growth entresto
best primari launch ever expect nrdl cosentyx great start challeng
maintain patient oop expect ndrl lucenti nrdl expect year
product list
 canakinumab comment interim analysi plan ahead primari complet
continu see good recruit adjuv recruit slower recruit expect
less patient expect bullish approach would like
 tasigna impact trf data play expect sustain growth us europ
growth us focu new switch pt strategi pay expect modest
 gross margin impact cell/gen therapi short term continu
lot focu improv manufactur capac gone
aspir improv margin come year
 expand access zolgensma could phenomenon pronounc ex-u
ex-u high degre interest alreadi put access program countri
east europ strong demand expect approv similar pent demand effect
oversea market
 think infrastructur launch
dilig prepar launch approv expect commerci focu
access get access approv quickli product impress impact patient
confid readi launch
compani mention price
